Acelyrin

Executive Summary

Acelyrin is a clinical-stage biopharmaceutical company focused on developing targeted biologic therapies for severe inflammatory and autoimmune diseases. Founded in 2020 and headquartered in Los Angeles, the company employs a business model of acquiring high-potential clinical assets and rapidly advancing them through development. Its lead product candidate is a monoclonal antibody targeting a key cytokine in immunology, currently in Phase 3 trials. Acelyrin has raised approximately $300 million to date, reflecting investor confidence in its pipeline and strategy. The company is publicly traded, though no ticker is provided. Acelyrin's approach aims to address significant unmet needs in immunology, but its success hinges on positive clinical data and regulatory approvals, which remain uncertain. The company's near-term outlook is driven by upcoming data readouts and potential regulatory milestones, which will determine its trajectory in the competitive immunology landscape.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 Topline Data for Lead Monoclonal Antibody60% success
• Q4 2026FDA Meeting or Regulatory Guidance for Lead Asset70% success
• Q1 2027Initiation of Phase 2/3 Trial for Pipeline Candidate50% success